First US Presentation of DETECT Data Demonstrates Semi-Quantitative Assessment of Endometriosis Lesions Using ^{99m}Tc-Maraciclatide

- *Poster presented at SNMMI 2026 shows standardised uptake metrics align with lesion type and expected levels of angiogenesis, including for superficial peritoneal disease*

London, UK, 30 May 2026. Serac Healthcare Limited ("Serac Healthcare" or "the Company"), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, ^{99m}Tc-maraciclatide, announces the presentation of a poster at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting reporting semi-quantitative imaging data from the DETECT Phase 2 study of ^{99m}Tc-maraciclatide in endometriosis.

The poster is available in the Science Pavilion throughout the meeting, which runs from 30 May to 2 June 2026 in Los Angeles and the author will be giving a brief introduction on its contents at a Meet the Author session from 1-1.45pm on Sunday 31st May in the Science Pavilion, South Hall GHJK (Convention Center); MTA01.

The DETECT study has previously demonstrated that SPECT-CT imaging with ^{99m}Tc-maraciclatide can visually detect endometriotic lesions, including superficial peritoneal disease which is not reliably visualised with existing imaging modalities. ^{99m}Tc-maraciclatide binds with high affinity to αvβ3 integrin, a receptor upregulated during angiogenesis, enabling the non-invasive localisation of active endometriotic lesions.

The poster presents new semi-quantitative analysis of imaging data from the DETECT study with known or suspected endometriosis who underwent SPECT-CT scanning with ^{99m}Tc-maraciclatide prior to laparoscopy. Standardised metrics were applied to regions of abnormal tracer uptake to derive measures of lesion size and specific uptake ratio, and compared with surgical findings. These metrics show alignment with the different sizes and expected levels of angiogenesis associated with superficial disease, deep disease, and endometriomas. The use of specific uptake ratios could provide a framework for an objective measurement of response to treatment.

Presenting the findings, **Dr Druin Burch, Chief Scientific Officer of Serac Healthcare**, said: "The development of robust semi-quantitative tools is an important step towards the clinical translation of maraciclatide. Standardised measures of uptake and lesion characteristics not only support reproducible image interpretation but also open the door to potential applications in monitoring disease activity and evaluating novel therapies."

David Hail, Serac Healthcare Chief Executive, added,
"Advancements in imaging for endometriosis have been identified as a global research priority. Currently, many women require invasive diagnostic laparoscopy and wait over nine years for definitive diagnosis. These data support the potential of imaging with maraciclatide to address this diagnostic gap."

-ENDS-

Maraciclatide is for investigational use only and is not approved by the FDA or UK and European regulatory authorities.

The (abstract #1985), "*Semi-quantitative Analysis of Endometriosis Subtypes Using ^{99m}Tc-Maraciclatide SPECT-CT*" is available on the SNMMI website and on the Serac Healthcare website. The poster will be available here after the meeting.

For more information, please contact:

Serac Healthcare Ltd	www.serachealthcare.com
David Hail, Chief Executive	+44 (0)20 8948 0000 info@seraclifesciences.com
Francetta Carr, Communications	+44 (0)7711 010820 francettacarr@seraclifesciences.com

Notes to Editors

Serac Healthcare Ltd

Serac Healthcare is a clinical radiopharmaceutical company with deep expertise in discovering, developing and commercialising innovative molecular imaging technologies. Using these targeted technologies to underpin personalised medicine in the fields of endometriosis, inflammatory arthritis and interstitial lung disease, Serac Healthcare is focused on bringing to market effective tools to accelerate diagnosis, and to deliver earlier and more effective treatment decisions. Serac Healthcare Ltd is a wholly owned subsidiary of Serac Life Sciences Limited. www.serachealthcare.com

About the Society of Nuclear Medicine and Molecular Imaging

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit snmmi.org.